ABSTRACT Introduction: The aim of this study was to assess the impact of aortic angulation (AA) on periprocedural and in-hospital complications as well as mortality of patients undergoing Evolut™ R valve implantation. Methods: A retrospective study was conducted on 264 patients who underwent transfemoral-approach transcatheter aortic valve replacement with self-expandable valve at our hospital between August 2015 and August 2022. These patients underwent multislice computer tomography scans to evaluate AA. Transcatheter aortic valve replacement endpoints, device success, and clinical events were assessed according to the definitions provided by the Valve Academic Research Consortium-3. Cumulative events included paravalvular leak, permanent pacemaker implantation, new-onset stroke, and in-hospital mortality. Patients were divided into two groups, AA ≤ 48° and AA > 48°, based on the mean AA measurement (48.3±8.8) on multislice computer tomography. Results: Multivariable logistic regression analysis was performed to identify predictors of cumulative events, utilizing variables with a P-value < 0.2 obtained from univariable logistic regression analysis, including AA, age, hypertension, chronic renal failure, and heart failure. AA (odds ratio [OR]: 1.73, 95% confidence interval [CI]: 0.89-3.38, P=0.104), age (OR: 1.04, 95% CI: 0.99-1.10, P=0.099), hypertension (OR: 1.66, 95% CI: 0.82-3.33, P=0.155), chronic renal failure (OR: 1.82, 95% CI: 0.92-3.61, P=0.084), and heart failure (OR: 0.57, 95% CI: 0.27-1.21, P=0.145) were not found to be significantly associated with cumulative events in the multivariable logistic regression analysis. Conclusion: This study demonstrated that increased AA does not have a significant impact on intraprocedural and periprocedural complications of patients with new generation self-expandable valves implanted. Introduction (AA inhospital Evolut implantation Methods 26 transfemoralapproach transfemoral approach selfexpandable self expandable 201 2022 endpoints success Consortium3. Consortium3 Consortium 3. 3 Consortium-3 leak newonset onset stroke groups 48 48.3±8.8 48388 8 (48.3±8.8 Results Pvalue P value 02 0 2 0. odds OR [OR] 173 1 73 1.73 95 CI [CI] 0.893.38, 089338 0.89 3.38, 89 38 0.89-3.38 P=0.104, P0104 P=0.104 , 104 P=0.104) (OR 04 1.04 0.991.10, 099110 0.99 1.10, 99 10 0.99-1.10 P=0.099, P0099 P=0.099 099 P=0.099) 166 66 1.66 0.823.33, 082333 0.82 3.33, 82 33 0.82-3.33 P=0.155, P0155 P=0.155 155 P=0.155) 182 1.82 0.923.61, 092361 0.92 3.61, 92 61 0.92-3.61 P=0.084, P0084 P=0.084 084 P=0.084) 057 57 0.57 0.271.21, 027121 0.27 1.21, 27 21 0.27-1.21 P=0.145 P0145 145 Conclusion implanted 20 202 Consortium- 4 48.3±8. 4838 (48.3±8. [OR 17 7 1.7 9 [CI 893 0.893.38 08933 089 0.8 338 3.38 0.89-3.3 P010 P=0.10 1.0 991 0.991.10 09911 0.9 110 1.10 0.99-1.1 P009 P=0.09 09 16 6 1.6 823 0.823.33 08233 082 333 3.33 0.82-3.3 P015 P=0.15 15 18 1.8 923 0.923.61 09236 092 361 3.61 0.92-3.6 P008 P=0.08 08 05 5 0.5 271 0.271.21 02712 027 121 1.21 0.27-1.2 P=0.14 P014 14 48.3±8 483 (48.3±8 1. 0.893.3 0893 3.3 0.89-3. P01 P=0.1 0.991.1 0991 11 1.1 0.99-1. P00 P=0.0 0.823.3 0823 0.82-3. 0.923.6 0923 36 3.6 0.92-3. 0.271.2 0271 12 1.2 0.27-1. 48.3± (48.3± 0.893. 0.89-3 P0 P=0. 0.991. 0.99-1 0.823. 0.82-3 0.923. 0.92-3 0.271. 0.27-1 48.3 (48.3 0.893 0.89- P=0 0.991 0.99- 0.823 0.82- 0.923 0.92- 0.271 0.27- 48. (48. P= (48 (4 (

SUMMARY Objective: Myocardial infarction has unfavorable effect on structural and functional properties of the myocardium, referred to as cardiac remodeling. Left ventricular mass, left ventricular mass index, and relative wall thickness are important predictors of cardiac remodeling. In this study, we investigated the effect of candesartan treatment in comparison with zofenopril treatment on echocardiographic indices of cardiac remodeling in post myocardial infarction patients. Material and Methods: In this prospective study, patients who underwent successful percutaneous coronary intervention were randomly assigned to a candesartan or zofenopril treatment. After randomization, echocardiographic indices of cardiac remodeling including left ventricular mass, left ventricular mass index, and relative wall thickness were evaluated before the start of treatment along with 1- and 6-month follow-ups. Results: According to our study, candesartan group showed significant reduction of estimated left ventricular mass and left ventricular mass index at 6-month follow-up visit compared to baseline values (199.53±38.51 g vs. 212.69±40.82 g; 99.05 g/m2 (90.00–116.5) vs. 106.0 g/m2 (96.0∼123.00), p<0.05, respectively). This trend was also observed in zofenopril group during the 6-month period (201.22±40.07 g vs. 207.52±41.61 g; 101.0 g/m2 (92.25–111.75.0) vs. 104.50 g/m2 (95.0∼116.75), p<0.05, respectively). Although both classes of drugs had favorable effects on post-myocardial infarction cardiac remodeling, the absolute benefit was more prominent in candesartan group as compared to zofenopril group (p<0.05). Conclusion: Our results suggest that candesartan treatment following myocardial infarction may potentially be useful in terms of improving post-myocardial infarction cardiac remodeling. Objective myocardium study Methods randomization 1 6month month 6 followups. followups follow ups. ups follow-ups Results followup up 199.53±38.51 199533851 199 53 38 51 (199.53±38.5 vs 212694082 212 69 40 82 212.69±40.8 9905 99 05 99.0 gm2 gm m2 m g/m 90.00–116.5 90001165 90 00 116 5 (90.00–116.5 1060 106 0 106. 96.0∼123.00, 96012300 96.0∼123.00 , 96 123 (96.0∼123.00) p005 p p<0.05 respectively. respectively . respectively) 201.22±40.07 201224007 201 22 07 (201.22±40.0 207524161 207 52 41 61 207.52±41.6 1010 101 101. 92.25–111.75.0 9225111750 92 25 111 75 (92.25–111.75.0 10450 104 50 104.5 95.0∼116.75, 95011675 95.0∼116.75 95 (95.0∼116.75) postmyocardial p<0.05. (p<0.05) Conclusion 199.53±38.5 19953385 19 3 (199.53±38. 21269408 21 4 8 212.69±40. 990 9 99. 90.00–116. 9000116 11 (90.00–116. 10 9601230 96.0∼123.0 12 (96.0∼123.00 p00 p<0.0 201.22±40.0 20122400 20 2 (201.22±40. 20752416 207.52±41. 92.25–111.75. 922511175 7 (92.25–111.75. 1045 104. 9501167 95.0∼116.7 (95.0∼116.75 (p<0.05 199.53±38. 1995338 (199.53±38 2126940 212.69±40 90.00–116 900011 (90.00–116 960123 96.0∼123. (96.0∼123.0 p0 p<0. 201.22±40. 2012240 (201.22±40 2075241 207.52±41 92.25–111.75 92251117 (92.25–111.75 950116 95.0∼116. (95.0∼116.7 (p<0.0 199.53±38 199533 (199.53±3 212694 212.69±4 90.00–11 90001 (90.00–11 96012 96.0∼123 (96.0∼123. p<0 201.22±40 201224 (201.22±4 207524 207.52±4 92.25–111.7 9225111 (92.25–111.7 95011 95.0∼116 (95.0∼116. (p<0. 199.53±3 19953 (199.53± 21269 212.69± 90.00–1 9000 (90.00–1 9601 96.0∼12 (96.0∼123 p< 201.22±4 20122 (201.22± 20752 207.52± 92.25–111. 922511 (92.25–111. 9501 95.0∼11 (95.0∼116 (p<0 199.53± 1995 (199.53 2126 212.69 90.00– 900 (90.00– 960 96.0∼1 (96.0∼12 201.22± 2012 (201.22 2075 207.52 92.25–111 92251 (92.25–111 950 95.0∼1 (95.0∼11 (p< 199.53 (199.5 212.6 90.00 (90.00 96.0∼ (96.0∼1 201.22 (201.2 207.5 92.25–11 9225 (92.25–11 95.0∼ (95.0∼1 (p 199.5 (199. 212. 90.0 (90.0 96.0 (96.0∼ 201.2 (201. 207. 92.25–1 922 (92.25–1 95.0 (95.0∼ 199. (199 90. (90. 96. (96.0 201. (201 92.25– (92.25– 95. (95.0 (19 (90 (96. (20 92.25 (92.25 (95. (1 (9 (96 (2 92.2 (92.2 (95 ( 92. (92. (92

ABSTRACT Background: The 2019 coronavirus (COVID-19) has precipitated a significant public health crisis. Our study aimed to evaluate the prevalence and risk factors associated with adverse reactions to the inactivated CoronaVac vaccine. Methods: The study involved voluntary health workers who received CoronaVac vaccine. We documented the sociodemographic information of 2,019 participants who volunteered for our study. Of these, 1,964 and 1,702 participants were interviewed by phone 1 month after the first and second dose, respectively, during which they were queried about any adverse reactions. Results: Within the first week after the first dose, adverse reactions were observed in 856 (43.3%) participants, with 133 (6.7%) experiencing them during the second week, and 96 (4.9%) people at the end of the first month. For the second dose, 276 individuals (16.2%) reported adverse reactions. The prevalence of both local and systemic adverse events ranged from 9.5-11.2% overall. Fatigue was the most common adverse reaction overall, while pain at the injection site was the most frequent local adverse reaction. Conclusions: The evaluation of both systemic and local side effects revealed no significant adverse reactions to the inactivated CoronaVac vaccine (Sinovac Life Sciences, Beijing, China). Our study found that the incidence of systemic and local adverse responses to the CoronaVac vaccination was lower than the rates reported in studies involving the recombinant adenovirus type-5, BNT162b1, and ChAdOx1nCoV-19 COVID-19 vaccines, all of which underwent the World Health Organization LULUC/PQ evaluation process. Background 201 COVID19 COVID 19 (COVID-19 crisis Methods 2 019 2,01 these 1964 964 1,96 1702 702 1,70 dose respectively Results 85 43.3% 433 43 3 (43.3% 13 6.7% 67 6 7 (6.7% 9 4.9% 49 4 (4.9% 27 16.2% 162 16 (16.2% 9.511.2% 95112 9.5 11.2% 5 11 9.5-11.2 overall Conclusions Sinovac Sciences Beijing China. China . China) type5, type5 type 5, type-5 BNT162b1 BNTb BNT b ChAdOx1nCoV19 ChAdOxnCoV ChAdOx1nCoV ChAdOx nCoV ChAdOx1nCoV-1 COVID-1 vaccines LULUCPQ LULUC PQ process 20 COVID1 (COVID-1 01 2,0 196 1,9 170 70 1,7 8 43.3 (43.3 6.7 (6.7 4.9 (4.9 16.2 (16.2 511 9.511.2 9511 95 9. 112 11.2 9.5-11. type- BNT162b ChAdOx1nCoV1 ChAdOx1nCoV- COVID- (COVID- 0 2, 1, 17 43. (43. 6. (6. 4. (4. 16. (16. 51 9.511. 951 11. 9.5-11 (COVID (43 (6 (4 (16 9.511 9.5-1 ( (1 9.51 9.5-

SUMMARY OBJECTIVE: Epicardial adipose tissue is a special form of visceral fat surrounding the heart. It is associated with cardiac and metabolic diseases. Epicardial adipose tissue is associated with risk factors for heart failure with preserved ejection fraction, such as obesity, metabolic syndrome, hypertension, and diabetes. In this study, we examined the importance of Epicardial adipose tissue as a predictor of heart failure with preserved ejection fraction. METHODS: Patients who were admitted to the Dicle University Medicine Faculty Heart Hospital between November 2013 and August 2014 were recruited for the study. The heart failure group consisted of 30 patients who were admitted to the cardiac intensive care unit, and the control group consisted of 30 patients who were admitted to cardiology polyclinics. We care about patients’ demographic and clinical features to be similar. Heart failure was diagnosed according to the European Cardiology Society 2012 heart failure guidelines. Epicardial adipose tissue was measured with a transthoracic parasternal long axis with an echocardiography device (GE Vivid S6). We compared the Epicardial adipose tissue measurements between the two groups. RESULTS: Epicardial adipose tissue was higher in patients with heart failure with preserved ejection fraction than in the control group (9.21±0.82 and 7.13±1.39 mm, respectively; p<0.001). Echocardiographic findings associated with left ventricular hypertrophy were intact ventricular septum (13.03±0.57 and 12.11±2.22 mm, respectively; p=0.013) and left ventricular mass index (131.13±18.00 and 117.90±20.30 g/m2, respectively; p=0.010). Findings associated with left ventricular diastolic dysfunction were as follows: left atrial volume index (60.71±21.53 and 44.92±9.93 mL/m2, respectively; p<0.001) and E/è (13.87±3.88 and 10.12±2.44, respectively; p<0.001) were higher in patients with heart failure with preserved ejection fraction than in the control group. Body mass index was not a significant indicator of obesity (p=0.097), but waist circumference was a significant indicator of visceral obesity (p<0.001). Logistic regression analyses indicated that Epicardial adipose tissue, age, left atrial volume index, left ventricular mass index, waist circumference, and E/é were significant in the Heart failure group; Epicardial adipose tissue was significant (p=0.012), and waist circumference significance was borderline (p=0.045). CONCLUSIONS: Epicardial adipose tissue was higher in patients with HF than in the control group, and Epicardial adipose tissue was a predictor of heart failure with preserved ejection fraction. In patients with heart failure with preserved ejection fraction, increased Epicardial adipose tissue means that Epicardial adipose tissue can be used as a biomarker of inflammation in the pathophysiology of heart failure with preserved ejection fraction.

SUMMARY OBJECTIVE: Intervention in chronic total occlusion lesions involves long procedure time, a serious contrast load, and complex procedures. In this study, we aimed to investigate mortality rate of patients who had procedural coronary angiography done for chronic total occlusion lesions in coronary angiography series and who developed contrast-induced nephropathy. METHODS: A total of 218 patients with chronic total occlusion lesion in at least one coronary artery, from three different medical centers, who underwent procedural coronary angiography were recruited for the study. Patient population was divided into two groups: those who developed contrast-induced nephropathy and those who did not. Mortality due to all causes was investigated between both groups throughout a 100-month follow-up. RESULTS: Mean age of patients with incidence of contrast-induced nephropathy was 66.7±11.8, and 23.8% of them were comprised by female. We found a significantly higher mortality in long-term follow-up in the patient group with contrast-induced nephropathy (42.9 vs. 57.1%, p≤0.001). According to Kaplan-Meier analysis performed additionally, survival during follow-up was significantly shorter in this group and, in logistic regression analysis, it was an independent predictor of mortality (OR 3.02; 95%CI 1.41–6.45, p=0.004). CONCLUSION: We identified that the development of contrast-induced nephropathy is associated with long-term mortality. It might be possible to reduce adverse events with prophylactic approaches before the procedure and close follow-up of such patients after the procedure.

SUMMARY OBJECTIVES: While studies on the treatment for the coronavirus disease 2019 (COVID-19) pandemic continue all over the world, factors that increase the risk of severe disease have also been the subject of research. Malnutrition has been considered an independent risk factor. Therefore, we aimed to investigate the clinical effect of dietary habits and evaluate the prognostic value of the Controlling Nutritional Status score in the COVID-19 patients we followed up. METHODS: A total of 2760 patients hospitalized for COVID-19 were examined. Patients were retrospectively screened from three different centers between September 1 and November 30, 2020. A total of 1488 (53.9%) patients who met the criteria were included in the study. Risk classifications were made according to the calculation methods of prognostic nutritional index and Controlling Nutritional Status scores and total scores. The primary outcome of the study was in-hospital mortality. RESULTS: The groups with severe Controlling Nutritional Status and prognostic nutritional index scores had a significantly higher mortality rate than those with mild scores. In the multivariable regression analysis performed to determine in-hospital mortality, the parameters, such as age (OR 1.04; 95%CI 1.02–1.06, p<0.001), admission oxygen saturation value (SaO2) (OR 0.85; 95%CI 0.83–0.87, p<0.001), and Controlling Nutritional Status score (OR 1.34; 95%CI 1.23–1.45, p<0.001), were independent predictors. The patient groups with a low Controlling Nutritional Status score had a higher rate of discharge with recovery (p<0.001). CONCLUSIONS: Higher Controlling Nutritional Status scores may be effective in determining in-hospital mortality in patients with COVID-19. Nutrition scores can be used as a useful and effective parameter to determine prognosis in patients with COVID-19.

SUMMARY OBJECTIVE: Severe inflammation is reportedly associated with subsequent cardiovascular events, including in patients with coronary artery disease. This study aimed to examine the prognostic value of systemic immune-inflammation index and determine mortality and clinical outcomes in patients with chronic coronary total occlusion. METHODS: Our study evaluated 366 consecutive coronary total occlusion patients. The clinical end points were all-cause mortality and major adverse cardiovascular events, which include target vessel revascularization, myocardial infarction, and cerebrovascular events during 105 months follow-up. RESULTS: The study findings showed 59 (16.1%) all-cause death, 22 (6%) target vessel revascularization cases, 32 (8.7%) myocardial infarction cases, and 13 (3.6%) cerebrovascular events cases, with a median follow-up of 49 months (26–74). Multivariate logistic regression analysis showed that systemic immune-inflammation index was not associated with target vessel revascularization, myocardial infarction, and cerebrovascular events. Multivariate Cox regression analysis found systemic immune-inflammation index to be associated with all-cause death. Kaplan-Meier analysis showed a lower survival rate and myocardial infarction-free survival time in patients with higher systemic immune-inflammation index scores. CONCLUSION: Although systemic immune-inflammation index is a preferable tool for the detection of mortality, it failed to give adverse outcomes. Larger multicenter studies are thus warranted to investigate the effect of systemic immune-inflammation index on clinical outcomes.

RESUMOObjetivos:Inflamação ocular é uma manifestação extra-intestinal comum de doença inflamatória do intestino (IBD) e pode ser paralela a atividade da doença. Neste estudo, investigamos se a espessura da coroideia pode ser útil para avaliar a atividade da IBD.Método:Um total de 62 olhos de 31 pacientes com IBD [10 com doença de Crohn (CD) e 21 colite ulcerosa (UC)] além de 104 olhos de 52 doadores de sangue saudáveis foram incluídos neste estudo. A espessura da coróide foi medida utilizando-se imagens de tomografia de coerência óptica com profundidade aprimorada. O índice de atividade da doença Crohn (CDAI) e o índice de Truelove Witts modificado foram usados para avaliar atividade da doença em CD e UC, respectivamente.Resultados:Não houve diferença significativa entre os pacientes com IBD e controles saudáveis em termos de medições da espessura da coróide subfoveal média em região 3000 μm nasal e 3000 μm temporal (p>0,05). Com base na análise univariada; idade, tabagismo, local do envolvimento em CD (ileal ou íleo-cecal), CDAI, atividade CD e índice de atividade endoscópica da UC foram significativamente correlacionados com a espessura da coróide (p<0,05). No entanto, fumar (p<0,05) e o local de envolvimento em CD (p<0,01) foram os únicos parâmetros independentes associados com um aumento na espessura da coroideia em todos os pontos de medida.Conclusões:A espessura da coroide não é um marcador útil para refletir a atividade da doença em pacientes com IBD, mas pode ser um indicador de envolvimento ileal em pacientes com CD.

ABSTRACTPurpose:Ocular inflammation is a frequent extraintestinal manifestation of inflammatory bowel disease (IBD) and may parallel disease activity. In this study, we evaluated the utility of a choroidal thickness measurement in assessing IBD activity.Methods:A total of 62 eyes of 31 patients with IBD [Crohn's disease (CD), n=10 and ulcerative colitis (UC), n=21] and 104 eyes of 52 healthy blood donors were included in this study. Choroidal thickness was measured using enhanced depth imaging optical coherence tomography. The Crohn's disease activity index (CDAI) and the modified Truelove Witts score were used to assess disease activity in CD and UC, respectively.Results:No significant differences in mean subfoveal, nasal 3000 μm, or temporal 3000 μm choroidal thickness measurements (P>0.05 for all) were observed between IBD patients and healthy controls. Age, smoking, CD site of involvement (ileal and ileocolonic involvement), CDAI, CD activity, and UC endoscopic activity index were all found to be significantly correlated with choroidal thickness by univariate analysis (P<0.05). Smoking (P<0.05) and the CD site of involvement (P<0.01) were the only independent parameters associated with increased choroidal thickness at all measurement locations.Conclusions:Choroidal thickness is not a useful marker of disease activity in patients with IBD but may be an indicator of ileal involvement in patients with CD.

Fundamento: A hipertensão arterial é o fator de risco mais prevalente e modificável para a fibrilação atrial. A sobrecarga de pressão no átrio esquerdo induz alterações fisiopatológicas que ocasionam alterações na função contrátil e nas propriedades elétricas. Objetivo: Nesse estudo, o objetivo foi avaliar a função do átrio esquerdo em pacientes hipertensos para determinar a associação entre a função atrial esquerda e a fibrilação atrial paroxística (FAP). Método: Foram estudados 57 pacientes hipertensos (idade: 53 ± 4 anos, fração de ejeção do ventrículo esquerdo: 76 ± 6,7%), incluindo 30 pacientes consecutivos com FAP e 30 indivíduos de controle pareados por idade. Os volumes do átrio esquerdo (AE) foram medidos através do método biplano de Simpson modificado. Foram determinados três tipos de volume do AE: volume máximo do AE (AEVmax), contração atrial prematura do AE (AEVpreA) e volume mínimo do AE (AEVmin). Foram calculadas as funções de esvaziamento do AE. Volume total de esvaziamento do AE = AEVmax - AEVmin e a FEtotal do AE = (AEVmax - AEVmin)/AEVmax, volume de esvaziamento passivo do AE = AEVmax-AEVpreA, e a FE do AE = (AEVmax - AEVpreA)/AEVmax, o volume de esvaziamento ativo do AE = AEVpreA- AEVmin e a FE ativa do AE = (AEVpreA - AEVmin)/AEVpreA. Resultados: O período hipertenso é maior no grupo de hipertensos com FAP. O AEVmax aumentou significativamente no grupo de hipertensos com FAP quando comparado ao grupo de hipertensos sem FAP (p = 0,010). A FEAE diminuiu significativamente no grupo de hipertensos com FAP em comparação com o grupo de hipertensos sem FAP (p = 0,020). A' diminuiu no grupo de hipertensos com FAP quando comparado com hipertensos sem FAP (p = 0,044). Conclusão: O volume aumentado do AE e função de esvaziamento ativa do AE prejudicada foram associados com a FAP em pacientes hipertensos não tratados. Um período hipertenso mais longo está associado com a FAP.

Background: Hypertension is the most prevalent and modifiable risk factor for atrial fibrillation. The pressure overload in the left atrium induces pathophysiological changes leading to alterations in contractile function and electrical properties. Objective: In this study our aim was to assess left atrial function in hypertensive patients to determine the association between left atrial function with paroxysmal atrial fibrillation (PAF). Method: We studied 57 hypertensive patients (age: 53±4 years; left ventricular ejection fraction: 76±6.7%), including 30 consecutive patients with PAF and 30 age-matched control subjects. Left atrial (LA) volumes were measured using the modified Simpson's biplane method. Three types of LA volume were determined: maximal LA(LAVmax), preatrial contraction LA(LAVpreA) and minimal LA volume(LAVmin). LA emptying functions were calculated. LA total emptying volume = LAVmax−LAVmin and the LA total EF = (LAVmax-LAVmin )/LAVmax, LA passive emptying volume = LAVmax− LAVpreA and the LA passive EF = (LAVmax-LAVpreA)/LAVmax, LA active emptying volume = LAVpreA−LAVmin and LA active EF = (LAVpreA-LAVmin )/LAVpreA. Results: The hypertensive period is longer in hypertensive group with PAF. LAVmax significantly increased in hypertensive group with PAF when compared to hypertensive group without PAF (p=0.010). LAAEF was significantly decreased in hypertensive group with PAF as compared to hypertensive group without PAF (p=0.020). A' was decreased in the hypertensive group with PAF when compared to those without PAF (p = 0.044). Conclusion: Increased LA volume and impaired LA active emptying function was associated with PAF in untreated hypertensive patients. Longer hypertensive period is associated with PAF.

Objetivo : Verificar se existe uma relação entre a hiperprolactinemia e distúrbios primários da tireoide, focando em pacientes com características autoimunes. Materiais e métodos : Os prontuários de 100 pacientes com hiperprolactinemia (HPRL) foram examinados retrospectivamente. Foram analisados registros de ultrassonografia da tireoide (USG), níveis séricos basais de hormônio tireoestimulante, tiroxina livre, triiodotironina livre e anticorpos antitireoglobulina (anti-Tg) e antitireoperoxidase (anti-TPO). Foram obtidos de 100 controles, pareados por idade e sexo com pacientes com HPRL, USG, testes de função da tireoide (TFTs) e painel de autoanticorpos. Resultados : A média de PRL em pacientes foi de 93 ng/mL (variação: 37-470). Vinte e cinco pacientes (25%) e 22 controles (22%) foram positivos para títulos de anti-Tg e/ou anti-TPO (P = 0,739). A mediana de PRL sérica foi de 98 (37-470) ng/mL em pacientes positivos para autoanticorpos tiroidianos e 92 (40-470) ng/mL em pacientes negativos (P = 0,975). Entre os indivíduos positivos para autoanticorpos, as anormalidades da TFTs foram mais frequentes em pacientes HPRL (60%; de 25 pacientes, 14 com hipotireoidismo subclínico e um com hipertireoidismo) do que nos controles (9,1%; de 22 pacientes, 2 com hipertireoidismo subclínico) (P < 0,001). Vinte e sete pacientes com HPRL e 31 controles apresentavam bócio (27 contra 31%; P = 0,437). Quarenta e seis pacientes (46%) e 50 (50%) controles tiveram uma ou mais das características de problemas de tireoide, como bócio, autoanticorpos antitireoide e anormalidades da função tiroidiana (P = 0,888). Conclusão : A HPRL pode estar associada à disfunção da tireoide mais grave em pacientes com autoimunidade contra a tireoide.

Objective : To establish whether there is a relationship between hyperprolactinemia and primary thyroid disorders, focusing on patients with autoimmune features. Materials and methods : The medical records of 100 patients with hyperprolactinemia (HPRL) were retrospectively examined. Records of thyroid ultrasonography (USG), basal serum levels of thyroid stimulating hormone, circulating free thyroxine, free triiodothyronine, antithyroglobulin (anti-Tg), and antithyroperoxidase (anti-TPO) antibodies were analyzed. In 100 control subjects, matched by age and gender with HPRL patients, thyroid USG, thyroid function tests (TFTs), and autoantibody panel were obtained. Results : The median PRL in patients was 93 ng/mL (range: 37-470). Twenty-five patients (25%) and 22 controls (22%) had positive anti-Tg and/or anti-TPO titers (P = 0.739). The median serum PRL was 98 (37-470) ng/mL in patients with positive thyroid autoantibodies, and 92 (40-470) ng/mL in patients who were negative (P = 0.975). Among the individuals with autoantibody positivity TFTs abnormalities were more frequent in HPRL patients (60%, out of 25 patients, 14 with subclinical hypothyroidism and one with hyperthyroidism) than in controls (9.1%, out of 22 patients, 2 with subclinical hyperthyroidism) (P < 0.001). Twenty-seven patients with HPRL and 31 controls had goiter (27 vs. 31%, P = 0.437). Forty-six patients (46%) and 50 (50%) controls had one or more of the features of thyroid disorder, which were goiter, positive thyroid autoantibody, and thyroid function abnormality (P = 0.888). Conclusion : HPRL may be associated with more severe thyroid dysfunction in patients with thyroid autoimmunity.